
Government of South Australia

InvestSA

South Australia
Clinical trials: Connected health innovation



The **Department of State Development**, a Government of South Australia agency, delivers sustainable economic growth and a resilient economy through the development of innovative and productive businesses and industries in South Australia.

Invest SA is South Australia's dedicated investment attraction unit, operating within the Department of State Development. We partner directly with domestic and international organisations, investors and industry leaders to identify commercial opportunities and enable successful market entry, expansion and collaboration.

Invest SA's specialised Health and Medical Industries team provides hands-on support throughout your investment journey connecting you with key industry, academia and government stakeholders.

We offer end-to-end case management for your business growth, including:

- Opportunity identification
- Dedicated case management
- Cross-government facilitation of investment projects
- Site and partner identification
- Guidance on state and federal incentives
- Introductions to sources of capital
- Promotion of opportunities in our key sectors to national and international investors

invest.sa.gov.au/sectors/health-and-medical

Acknowledgement of Country

We acknowledge the Traditional Owners of the land of South Australia and pay our respects to Elders past and present.

We acknowledge this land, its people, and the stories that connect the two. They are stories of place, as old as time, and they are part of our story today and into the future.

Contents

Our strengths are your opportunities 04

Uniquely connected health ecosystem 06

End-to-end clinical trial capabilities 08

Key opinion leaders 10

Clinical trial service providers 13

Public clinical sites 20

Research organisations 24

Leading the nation in artificial intelligence for healthcare 30

Case studies: AI is changing the way we think health 33

Global technology leaders are here 34

World-class innovation places 36

Let's talk 40

Cover image: Human breast cancer cells | Image courtesy of 10X Genomics

Our strengths are your opportunities

Complete clinical trial ecosystem

Clinical trials data accepted by global regulatory agencies.

Australia's best longitudinal clinical data set

Statewide electronic medical record linked to Australia's largest pathology and medical imaging providers.

Advanced technological capabilities

Artificial intelligence, augmented and virtual reality (AR/VR), quantum, data analytics and computer vision leadership.

World-class health and medical ecosystem

One of the world's most connected and technologically advanced precincts.

State-of-the-art GMP manufacturing

R&D to commercial scale, small and large molecules and radiopharmaceuticals.

Leader in cancer research, clinical translation and care

Key opinion leaders, research institutions and isotope synchrotron for clinical research and care

R&D tax incentive program up to 43.5%

Supporting companies across R&D activities in Australia.

At the forefront of biotech R&D

World-class biotech, including vaccine, microbiome and CAR T-cell research.

Advanced device manufacturing capabilities

Expertise and capability for ISO 13485.

Pioneering global innovation

South Australia gained the world's first microbiome therapy approval[1] and the first to revolutionise x-ray technology.[2]

More than 150 health and medical companies within a 20-minute radius

Over 4,000 researchers with deep health expertise.

Bench-to-bedside capability

Leading medical practitioners and experts working across public hospitals, academia and private practice to advance local and global clinical research.

1 CosmosID 2022, Australia to Become the First Country to Approve Fecal Transplant to Restore Gut Health
2 Australian National Fabrication Facility-South Australia 2020, Mobilising life-saving portable x-ray systems across the globe

Connected innovation districts

Adelaide's flagship Innovation Places include Adelaide BioMed City, a A$3.8 billion investment, Lot Fourteen, focused on critical technologies, and Tonsley Innovation District, centred on advanced manufacturing. These locations feature state-of-the-art infrastructure combined with world-class researchers, industry, government, and academia, fostering high levels of integration and collaboration.

With Adelaide BioMed City, Lot Fourteen, Adelaide University and Flinders University within close proximity to each other in the central business district, South Australia offers a unique clustered environment where health and medical research, manufacturing and clinical care are integrated with technology innovation.

End-to-end clinical trial capabilities

Australia's streamlined regulatory framework enables fast timelines for clinical trial conduct delivering data recognised by key global regulators such as the TGA, FMA, EMA, MHRA, MFDS and PDMA. Clinical trials may commence in as little as six weeks.

South Australia offers a unique and efficient ecosystem for clinical trials, serving as an ideal entry point into the Australian clinical research sector. Clinical trials in South Australia are cost-effective, highlighted by the Australian Research and Development Tax Incentive Program of up to 43.5 per cent and significant time savings.

Data-driven and precision health innovation

Adelaide is home to world-leading artificial intelligence, data analytics and virtual reality capabilities, supported by unique clinical infrastructure, longitudinal datasets and biospecimens for precision health innovation.

Australia's first facility solely dedicated to artificial intelligence research, the Australian Institute for Machine Learning (AIML), conducts globally renowned research in machine learning, artificial intelligence, computer vision and deep learning and collaborates with industry across sectors to develop high-tech products and solutions.

AIML works with leading global companies, including Roche, GSK, Sanofi and Medtronic, to push the frontier of precision health.

Drug development and biotech

South Australia is a centre for drug research across a wide range of indications, including oncology, immunology, infectious diseases, neuroscience and endocrinology.

Oncology is a focus, including precision health, CAR T-cell technology, computational systems, epigenetics, single cell and spatial technologies, gene regulation, molecular signaling, translational oncology and cancer genomics.

Manufacturing capability

Australia's commercial drug manufacturing pedigree is founded in South Australia, which features many of its leading academic manufacturing resources and oldest established commercial operations.

South Australia's contract development and manufacturing organisations (CDMOs) support process development through to clinical and commercial scale manufacturing for global markets to Good Manufacturing Practice (GMP), for biologics and small molecules.

South Australia offers radiopharmaceutical manufacturing, including access to radio isotopes.

Expertise spans therapeutics (biologics and small molecules), vaccines, medical devices, nutraceuticals, traditional medicines, and radiopharmaceuticals to GMP requirements.



SAHMRI | Image courtesy of Meaghan Coles

Uniquely connected health ecosystem




Illustration of Adelaide Central Business District

South Australia is characterised by deep clinical research, manufacturing and an end-to-end value chain supported by world-class infrastructure and digital capabilities. It is an exceptionally collaborative and connected ecosystem for drug development, advanced manufacturing and data-driven health innovation. **This makes Adelaide and South Australia the perfect location to collaborate, innovate and trial new products, ready for global commercialisation.**

Innovation precinct – Adelaide BioMed City

Adelaide BioMed City is one of the most technologically advanced health and life sciences research districts globally and is situated in the heart of Adelaide. Consisting of cutting-edge anchor institutes and companies that collaborate with start-ups, business incubators, and accelerators, the A$3.8 billion innovation district provides mixed-use facilities where researchers, clinicians, and students work alongside entrepreneurs and leading industry players. Adelaide BioMed City houses over 30 clinical trial rooms that deliver high-impact translational research, creating positive impacts both nationally and internationally.

With more than 2,000 researchers and 10,000 staff, the industry brings together institutes and centres from health and life sciences, clinical care, research, education and industry. The district is home to a range of specialist research institutes and organisations supported by a world-class genomics capability, a cancer research biobank, and the country's largest public pathology and medical imaging capabilities.

Combining Australia's most experienced end-to-end clinical trial supply chain with a regulatory framework that provides the fastest pathway to first-in-human (FIH), Adelaide BioMed City enables clinical trial conduct for submission to global regulatory agencies. Adelaide BioMed City incorporates state-of-the-art, FDA-accredited Good Manufacturing Practice (GMP) manufacturing, servicing research and development to commercial scale.

The district is build around leading academic, industry and public institutions which together offer a true bench-to-bedside capability with a focus on research translation to improve health outcomes for patients.

Adelaide BioMed City is home to key health and medical research institutions including:

- Royal Adelaide Hospital
- South Australian Health and Medical Research Institute
- South Australian immunoGENomics Cancer Institute (SAiGENCI)
- Flinders University City Campus
- Adelaide University College of Health and Centre for Cancer Biology.



SAHMRI Building | Image courtesy of SAHMRI

End-to-end clinical trial capabilities

South Australia provides the fastest pathway for clinical trial conduct with data accepted by regulatory agencies globally, offering speed, quality and value in medical research.



South Australian Advantage

Australia's most experienced providers operate in South Australia, creating the nation's most comprehensive, connected and supportive clinical trial ecosystem, providing leadership across the entire supply chain:

- Local ethics approval and an advanced ecosystem allows you to start trials in five to six weeks.
- Save resources by working with experienced partners who offer specialised advice; increasing efficiency, reducing risk, and adding value during your trial exploration, setup, and conduct.

Our unique ecosystem provides a trusted, connected environment for you to partner and innovate.

Start in South Australia to leverage the Australian opportunity

Speed

Efficient regulatory framework saves up to one year in regulatory timelines.

Investigational new drug application (IND) not required for Phase I studies.

Quality

Globally accepted data with the highest quality standards for submission to regulatory agencies including the US FDA, UK MHRA, EU EMA, and Japan PDMA.

Value

R&D tax incentive program up to 43.5%.

Complete clinical trial ecosystem



Key opinion leaders

World-leading medical researchers and clinicians are advancing global clinical research. In Australia, medical doctors usually practice across public hospitals, academia, as well as private practice, embedding a bench-to-bedside capability.



Dedicated principal investigators include:

Professor Jenny Couper, MBChB, FRACP, MD

Expertise: Type 1-diabetes; nutrition and metabolic health; cardiac, respiratory and vascular health; immunology and infection; translational health outcomes; paediatrics; endocrinology.

Professor Maria Makrides BSc, BND, PhD, FAA, FAHMS, FNSA

Expertise: Nutrition and dietetics; maternal and child health; pregnancy and perinatal health.

Professor Alice Rumbold PhD, MPH, BSc(Hons)

Expertise: Reproductive health, maternal and child health, Indigenous health research.

Professor Michael P. Brown PhD, MBBS Hons I, FRACP, FRCPA

Expertise: Clinical immunology; medical oncology; gene therapy; immunotherapy.

Professor Chris Karapetis MBBS, MMedSci (Clin Epi), FRACP

Expertise: Medical oncology; molecular targeted therapies; predictive biomarkers; epidemiology.

Professor Tim Price MBBS, FRACP, DHlthSc, MAID

Expertise: Gastro-intestinal and Neuroendocrine cancers; cancer biology and drug discovery; molecular oncology; supportive care, cancer therapy.

A/Professor Rohit Joshi MBBS, MD, FRACP, FACP, FRCP

Expertise: All solid cancers including lung, breast, gastro-intestinal and kidney cancers; cancer biology and clinical oncology; tumour immunology; cancer therapy.

Professor Deborah White PhD, FFSc (RCPA)

Expertise: Leukaemia; cancer biology and clinical oncology; translational health outcomes.

Professor Paul Rolan MBBS, MD, FRACP, FFPM (UK), FFPMANZCA

Expertise: Neuroscience, behaviour and brain health; chronic pain; cellular immunology; pharmacology; pain; indigenous and disadvantaged health.

Dr Paul Wabnitz BSc, MD, PhD, MBA, FRACP

Expertise: Pharmacology, toxicology, clinical medicine; drug development; precision medicine; translational medicine; immunology.

Professor Andrew Bersten, MB, BS, MD, FANZCA, FJFIC

Expertise: Critical care medicine, Respiratory medicine.

Professor Jodie Dodd, MBBS, PhD, FRANZCOG, DDU, CMFM

Expertise: Nutrition and metabolic health; pregnancy and birth; translational health outcomes; early origins of health.

Professor Helen Marshall MBBS, DCH, MPH, MD

Expertise: Vaccinology, immunology, infectious diseases; child health, public health.

Professor Jordan Hansford, BSc (Hons), MSc, MBBS, FRACP

Expertise: Paediatric brain tumours; cancer genetics; stem cell medicine.

Professor Timothy P. Hughes MD, FRACP, FRCPA, MBBS, FAAHMS

Expertise: Chronic leukemias and myeloproliferative disorders; cancer cell biology; cancer genetics and cancer therapy; haematology; cancer biology and clinical oncology.

Dr Ganessan Kichenadasse MBBS, FRACP, M Clin Edn, PhD

Expertise: Oncology including brain, gynaecological, genitourinary (bladder, kidney, prostate), sarcomas, breast, thyroid cancers, cancer of unknown primary and other rare cancers.

A/Professor Michael Osborn MBBS, FRACP, FRCPA

Expertise: Acute lymphoblastic leukaemia (ALL); cancer in adolescents and young adults (AYA); paediatric chronic myeloid leukaemia (CML) and other haematological malignancies in children and AYA; cancer survivorship.

Professor Christopher Sweeney MBBS, MD

Expertise: Genitourinary malignancies; haematology; oncology; men's health; pharmacogenetics; personalised medicine.

Professor Guy Ludbrook PhD, MBBS, FANZCA

Expertise: Pharmacology, anaesthesia, health systems, health services, health economics, medical devices, clinical trials - phase I to phase III, neuropharmacology.

Professor Sepehr Shakib PhD, MBBS, FRACP

Expertise: Clinical pharmacology; chronic heart failure; internal medicine.

Professor Stuart Brierley PhD, BSc, BSc Hons

Expertise: Chronic visceral pain; neuroimmune interactions in the gut; novel pain therapeutics.

Associate Professor David Schultz, BMBS, FRACP

Expertise: Motor neuron disease; stroke; migraine; and multiple sclerosis.

Professor Peter Psaltis, (MBBS (Hons), PhD, FRACP, FCSANZ, FESC)

Expertise: Cardiovascular medicine; haematology; immunology and infection; stem cell biology; atherosclerosis; vascular regeneration.

Above is a selection of key opinion leaders only. Please contact our team for information on other industry leaders.

Clinical trial service providers

Australian Teletrial Program

Australian Teletrial Program – South Australia (ATP-SA) is expanding clinical trials to rural, regional and remote South Australians by connecting isolated “satellite” sites to a primary site.

Teletrials provide improved capability to recruit trial participants from rural South Australia and promote diversity, equity and inclusion by increasing data collection diversity and including Aboriginal and other vulnerable communities in the trial.

The hub-and-spoke cluster model reduces contract complexity for sponsors.

Part of a nation-wide program, ATP-SA is building a more interconnected clinical trials system and expanding the reach of clinical trials in South Australia. This increases the potential trial population by 50% (1.4 million > 1.8 million).

ATP-SA is increasing the capacity and capability of regional health services to see clinical trials as business as usual. The ATP-SA team can provide education and support all aspects of clinical trials including feasibility, study start-up logistics, regulatory processes, clinical trial coordination, protocol development to establish clinical trials and digital/telehealth support.

sahealth.sa.gov.au/saclinicaltrials

Cancer Research SA

Cancer Research SA (CRSA) is a purpose built clinical research organisation specialising in advancing cancer care with the efficient delivery of Phase I (including first in human, dose escalation, and expansion studies), II, and III oncology clinical trials.

CRSA offers comprehensive expertise across solid tumours, including breast, lung, genitourinary (prostate, bladder, kidney, and testicular), gynaecological (ovarian, uterine, and cervical), gastrointestinal (oesophageal, gastric, hepato-biliary and colorectal), and melanoma.

Early Phase Expertise (supporting complex Phase I designs, adaptive protocols, and novel mechanisms of action), Rapid Study Start Up & Speed to First Patient (efficient regulatory and ethics framework enables streamlined approvals, predictable timelines, and rapid site activation), GCP & Global Regulatory Alignment (studies are conducted in full compliance), High Quality Data & Operational Reliability (focused on protocol adherence, accurate data capture, safety reporting, and consistent execution across the trial lifecycle), Integrated Multidisciplinary Model (collaboration with experienced medical oncologists, specialist surgeons, radiation oncologists, and allied health teams ensures safe conduct of intensive early phase protocols) and Sponsor Responsive Partnership (Direct access to senior clinical and operational leadership, clear communication, and flexible site operations tailored to sponsor and CRO needs).

Working in close collaboration with national and international research organisations, pharmaceutical and biotechnology partners, and leading cancer surgeons, radiation oncologists, and medical specialists, CRSA provides an integrated, patient centred research environment. This collaborative model ensures that each patient’s care is individualised, optimised, and delivered to the highest international standards, while enabling sponsors and collaborators to conduct efficient, high quality clinical research in Australia.

crsa.au

SAHMRI | Image courtesy of Meaghan Coles

CMAX Clinical Research

CMAX Clinical Research (CMAX) has been a leader in delivering early phase clinical trials and first-in-time human (FIH) studies for over 30 years. CMAX is one of Australia's oldest, most respected and successful clinical trial sites in Australia.

CMAX has a proven track record of experience and innovation in early phase clinical research and a depth of clinical pharmacology expertise within the team. Their modern clinical trial unit is equipped with 78 inpatient beds and located within Adelaide's BioMed City provide ready access to state-of-the-art facilities, and world-class medical specialists.

CMAX has designed and delivered more than 800 early phase clinical trials, including more than 200 FIH studies for clients in the pharmaceutical, biotechnology and devices fields. They are FDA-and TGA-audited and EMA, PMDA and Health Canada-compliant.

CMAX's services are eligible for the Australian R&D Tax Incentive program, allowing eligible companies to claim a rebate of up to a 43.5% on qualifying R&D spend.

cmax.com.au

Southern Oncology Clinical Research Unit

Southern Oncology Clinical Research Unit (SOCRU) is a leading clinical research organisation, located within the Flinders Private Hospital, specialising in conducting Phase I oncology clinical trials. The organisation is staffed by a team of highly skilled and experienced clinical research professionals who are dedicated to advancing cancer research. SOCRU has extensive experience in conducting trials using a variety of interventions, including cytotoxic agents, targeted therapies, immunotherapy and oncolytic viral and cell therapies.

SOCRU places a strong emphasis on ethical research practices, patient safety and works closely with regulatory authorities to ensure that all trials meet the highest quality and regulatory standards. By conducting rigorous clinical trials, SOCRU aims to contribute to the development of new cancer treatments that can provide better outcomes for patients and improve the quality of life for people living with cancer.

socru.org.au

Fusion Clinical Research

Fusion Clinical Research supports the medical community to provide later-stage clinical trials to patients in a general practitioner's (GP) setting.

Located close to the city, in Norwood, Fusion maintains a volunteer database of 10,000+ and leverages an extensive GP/specialist network to connect pharma, biotech, digital health, and CROs with participants ready to participate in clinical trials.

They specialise in two areas: vaccination clinical trials and patient treatment clinical trials. Their skilled team of doctors, nurses, and scientists ensures high-quality client service, patient care, and trial execution.

Fusion's track record includes:

- 97% retention rate through 2025
- 97% enrolment-to-target rate through 2025
- strong repeat enrolment from past participants
- consistent "first-patient-in" achievement and top recruiter rankings

fusiontrials.com.au

Contract development and manufacturing organisations (CDMOs)

BioCina

BioCina is a global, end to end contract development and manufacturing organisation (CDMO) headquartered in Australia, serving pharmaceutical and biotechnology clients from early clinical development through to commercial supply. With integrated GMP facilities spanning biologics drug substance and sterile fill finish drug product, BioCina is the leading end to end CDMO in Australia.

Their drug substance capabilities include microbial fermentation, plasmid DNA (pDNA), mRNA, and lipid nanoparticle (LNP) encapsulation, supporting programs from cell banking through to purified bulk material at clinical and commercial scale. Drug product capabilities cover the full spectrum of sterile fill finish for both small molecules and biologics, across multiple presentations including Blow Fill Seal (BFS), aseptic vials, prefilled syringes, cartridges, cytotoxic fill finish, and controlled substance manufacturing.

Trusted by leading regulatory authorities including the US FDA, EMA, TGA, PMDA, and Health Canada, BioCina has supported more than 600 product approvals globally. For sponsors conducting clinical trials in Australia, BioCina offers phase appropriate, flexible clinical trial supply with drug substance and drug product delivered under a single, integrated project team.

biocina.com

Mayne Pharma

Mayne Pharma is a full-service contract development and manufacturing organisation (CDMO) that offers pharmaceutical development and manufacturing from their GMP and FDA-accredited Australian plant.

Mayne Pharma partners globally to develop pharmaceutical products from concept to commercialisation quickly and cost-effectively. They offer seamless development which includes manufacture of clinical trial supplies, scale-up of new formulations and technology transfer of products through to commercial production.

Mayne Pharma has a 40-year history of successfully developing and manufacturing oral and topical products for the global market. Their expertise includes formulation development of modified release capsules, tablets, semi-solid and liquids, using best practice assessment techniques and specialised equipment.

From their manufacturing facility in South Australia, Mayne Pharma provides a team of highly skilled scientists to assist with developing, validating, and optimising testing procedures, as well as managing the complexities of regulatory submissions.

maynepharma.com

Contract research organisations (CROs)

Avance Clinical

Avance Clinical (Avance) is a premium full-service contract research organisation (CRO) headquartered in Australia with significant operations across New Zealand, Asia, North America and Europe. Avance is delivering quality clinical trials, with globally accepted data for international biotechs and pharma. Avance offers comprehensive pre-clinical services through to late phase studies, leveraging the Australian Advantage of significant government incentive rebates of up to 43.5%, no IND requirement, and rapid start-up regulatory processes.

Avance is the market leader in Early Phase clinical trials providing international biotechs with fast, agile and adaptive solution-oriented clinical research services. With experience across more than 250+ indications across all therapeutic areas, Avance delivers high-quality data recognised by key global regulators, including the TGA, FDA, EMA, MHRA, MFDS, and PDMA.

Avance Clinical uses state-of-the-art technology and gold-standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, and Medrio are some of their technology partners.

avancecro.com

Syneos Health

Syneos Health is a global, fully integrated biopharmaceutical solutions company committed to helping biotech and pharmaceutical companies navigate and optimise pathways to success. They translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities.

Syneos Health brings together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviours and market dynamics. Together they share insights, use the latest technologies and apply advanced business practices to speed their customers' delivery of important therapies to patients.

With expertise in drug development in Australia, Syneos Health's Adelaide office provides valuable insights into the pharmaceutical, biotech, and medtech landscape, as well as into the conduct of clinical programs to facilitate the development and commercialisation of new medical and healthcare assets.

syneoshealth.com



Drug storage and distribution

Zuellig Pharma SSG Australia

Zuellig Pharma SSG Australia, as part of the Zuellig Pharma Group, is a leader in delivering best-in-class clinical trial supply and logistics services, and one of the largest healthcare solutions in Asia.

With a proven record of over 27 years of experience, their Australian facility has supported over 1,400 clinical trials, predominantly in Australia and New Zealand, spanning phase I, II, III, and IV studies, SAS supply, and direct-to-patient services.

Services include:

- clinical storage and distribution
- cold chain management
- global and local clinical sourcing
- secondary packaging and labelling
- local and global project management
- regulatory insight (Import of Record-IoR, Export of Record-EoF, Release For Supply-RFS) and assistance
- returns and destruction management
- direct-to-patient supplies, including depot-to-patient, site-to-patient and direct-from-patient.

zuelligpharma.com

Ethics

Bellberry Limited

Bellberry Limited (Bellberry) is an Australian, independent, not-for-profit organisation providing streamlined scientific and ethical review of human research projects across all phases of clinical and device trials, and social and behavioural studies across private, public, academic and government sectors. Bellberry aims to protect the welfare of research participants and improve the quality, efficiency and effectiveness of research.

Founded 21 years ago, Bellberry initially focused on providing specialist scientific and ethical review for research conducted in the private health sector and has since evolved into the single largest reviewer of clinical research in Australia.

Bellberry holds weekly Human Research Ethics Committee (HREC) meetings, providing specialist oversight to at least one third of Australia's clinical trial notification (CTN) registered clinical trials annually. Their 125+ HREC members have reviewed over 4,000 studies since its beginnings in 2004.

Bellberry is at the forefront of global drug development and is the first organisation in Australia to achieve international accreditation for excellence and ethically sound processes in running HRECs by the Association for the Accreditation of Human Research Protection Programs (AAHRPP).

As a not-for-profit, Bellberry redistributes any surplus from its professional review service back into the research sector community to support the advancement of research knowledge through philanthropy and education.

Bellberry provides real-time expert insight on regulatory processes, including ethics, governance and start-up processes.

bellberry.com.au

Regulated bioanalysis and toxicology

Agilex Biolabs

Agilex Biolabs is Australia's largest FDA-inspected bioanalytical laboratory, with nearly 30 years' experience in regulated bioanalysis. Their laboratories feature state-of-the-art equipment, including Sciex Triple Quad 6500+, MSD Quickplex 120, Cytek Aurora, BD FACSymphony A3, and droplet digital PCR, enabling comprehensive bioanalytical services.

Agilex holds ISO/IEC17025 accreditation, OECD GLP recognition with NATA, and ISO27001:2022 certification for information security, ensuring the highest quality standards.

They operate from two locations, Adelaide and Brisbane, to support clinical trials across Australia. Agilex Adelaide, its headquarters, is FDA-inspected and houses almost 200 staff across LC/MS, Immunoassay, and Immunobiology divisions, forming Australia's largest bioanalytical team. Agilex Brisbane features a modern flow cytometry lab and PBMC isolation room, allowing rapid sample processing and fast data turnaround.

A global leader in flexible solutions, Agilex Biolabs has accelerated numerous pharmaceutical and biopharmaceutical drug development programs across the US, APAC, and EU, supporting diverse drug modalities and therapeutic indications with reliable, high-quality bioanalytical expertise.

agilexbiolabs.com

Gnomix

With experience spanning four decades of growth and development in the molecular genetic industry, GNOMIX provides a one-stop shop for a broad range of molecular solutions, tailored to meet individual client requirements.

Combining client engagement with experience and extensive professional network, GNOMIX is committed to collaborating with clinical researchers, CROs and clinical trial units to provide personalised quality solutions to meet the scale, data content, financial and time constraints of their projects.

GNOMIX is accredited by NATA to ISO/IEC 17025 standard for laboratory testing.

Services include:

- molecular laboratory services: DNA and RNA extraction and quality control, PCR and sequencing
- sequence analysis: DNA and RNA assay and sequencing from individual SNPs to exome or transcriptome analysis
- expression analysis: off-the-shelf and custom-design assays for gene expression analysis
- precision custom solutions: holistic tailored solutions
- consultancy.

gnomix.com.au

South Australian Genomics Centre

The SAGC (South Australian Genomics Centre) is the only NCRIS-enabled state-wide genomics facility in South Australia, supporting research and industry partners across disciplines, both nationally and internationally.

SAGC delivers a comprehensive suite of genomics and bioinformatics services, including RNA sequencing, whole genome sequencing (WGS), whole exome sequencing (WES), epigenomics, metagenomics, and advanced single-cell and spatial transcriptomics.

Ultra High-Throughput Sequencing Capability:

- ISO/IEC 17025 Accredited Laboratory
- dedicated team of Genomic Scientists and Bioinformaticians

Single Cell Transcriptomics Service:

- SAGC offers a variety of single cell technologies and application types: gene expression, immune profiling, epigenetics, CRISPR library detection.
- complete toolkit from 10X Genomics
- certified service provider for Parse Biosciences.

Spatial Transcriptomics Service:

SAGC is the only Genomics Centre in Australia offering 10X Genomics platforms (Xenium in situ analyser, Visium HD), Stereo-seqTM STOmics from MGI Australia and CosMx SMI from Nanostring Bruker. The SAGC has two locations: SAHMRI and Flinders Health and Medical Research Institute (FHMRI), conveniently located near three major research hospitals: The Royal Adelaide Hospital, the new site for the Women's and Children's Hospital, and Flinders Medical Centre.

sa-genomics.com.au

R&D incentives, accounting and corporate services

RDI Partners

RDI Partners is an award-winning, globally connected provider of a full range of corporate and management services enabling foreign-owned and controlled biotech/medtech companies to establish a presence in Australia, conduct research and development (R&D) activities and benefit from the R&D tax incentive.

RDI Partners has supported over A$750 million in R&D investments by foreign-owned biotech companies in Australia operating through an Australian presence.

The RDI Partners competitive advantage is underscored by:

- a full-service model, including company establishment and structuring, resident director, accounting and tax, R&D tax, advanced/overseas findings and finance
- depth of technical knowledge in R&D tax, biotechnology and corporate structuring
- track record of seamless service delivery, R&D tax outcomes and overseas finding successes
- strength of relationships with clinical service providers through Australia
- low-cost and low-risk pricing model of a fixed quoted fee where fees are linked to outcomes with no ongoing retainers or monthly charges.

rdipartners.com.au

Bentleys

Independently owned and operated in South Australia for over 45 years, Bentleys is an integrated business services and advisory firm.

Bentleys advisory services are strengthened by a range of specialisations, enabling them to support the broad needs of individuals and enterprises at every stage of the business lifecycle. In addition to business advisory, accounting, audit, and taxation services, they specialise in business advancement advice, financial planning and wealth management, including self-managed super funds, taxation consulting, R&D tax incentive services and advice, business and residential finance, and corporate recovery services.

Bentleys supports businesses and individuals throughout South Australia and is a member of the Bentleys Network and Allinial Global. With their local expertise, national presence and international capability, they work with enterprises at every stage of their business journey.

bentleys.com.au

Public clinical sites

Central Adelaide Local Health Network (CALHN)

The Central Adelaide Local Health Network (CALHN) is South Australia's largest health network, serving almost 30 per cent of the population. With over 17,000 staff and more than one million patients, they deliver public health services to two major Adelaide hospitals, the Royal Adelaide Hospital and the Queen Elizabeth Hospital, and a range of rehabilitation and mental health facilities.

Royal Adelaide Hospital

The 800-bed Royal Adelaide Hospital is one of Australia's most technologically advanced healthcare facilities and the state's flagship hospital, providing a comprehensive range of the most complex clinical care to an estimated 85,000 inpatients and 400,000 outpatients each year.

Located within Adelaide BioMed City, the state-of-the-art facilities appeal to healthcare professionals, helping to attract some of the best expertise from around the world.

The Royal Adelaide Hospital features:

- a purpose-built Clinical Trials Centre with advanced facilities designed to meet the needs of clinical trial patients and optimise patient flow
- leading telehealth facilities that enable staff to consult with colleagues and patients in regional and remote areas across the state and further afield, while digital imaging technology allows clinical images to be streamed live from operating theatres and procedural rooms for diagnostic and training purposes
- the largest automated microbiology system, providing world-class technology to support the timely diagnosis and treatment of infectious diseases
- one of the biggest automated pharmacy distribution systems in the nation, bringing South Australia to the forefront of automated medication technology
- the state's only public hospital with a digital instrument tracking system to manage its vast collection of medical equipment.



Adelaide EpiCentre

The Adelaide EpiCentre (Centre for Clinical Epidemiology) is a state-of-the-art health informatics, biostatistics, health economics and epidemiology centre. Its research activities revolve around clinical epidemiology with the aims of improving access to and outcomes of health care.

Based at the Royal Adelaide Hospital, the Adelaide EpiCentre's objectives are to grow research and research translation; support clinical researchers with advice, training and mentorship; and optimise health service delivery through data-driven insights.

Some of the Centre's key functions are:

Support in clinical and applied research

- advice on study design and clinical epidemiology
- advice and support for data management (e.g., linked data) and analyses (e.g., biostatistics)
- advice about ethics and governance issues related to data use in a health setting.

Health services research

- facilitate the use of routinely collected health and EMR data for research and service improvement
- use of data to drive health service planning and evaluation.

Research translation and implementation

- support to improve the real-world relevance of research
- support for implementation of research findings into practice and policy.

Health economics

- quantification of the economic burden of ill-health
- economic evaluation of health interventions complementary to other fields of research
- evaluation of the impact of health programs in hospitals or other settings, to refine programs and inform practice and policy.

Teaching, training and mentorship

- supervision of higher research degrees
- research mentorship
- short courses
- ad-hoc advice to clinicians, researchers and students.

The Queen Elizabeth Hospital

The Queen Ellizabeth Hospital is a 355 bed, acute and sub-acute care teaching hospital that provides inpatient, outpatient, emergency and mental health services to a population of more than 250,000 people living primarily in Adelaide's western suburbs.

Clinical trials

The Queen Elizabeth Hospital Cancer Clinical Trial Unit specialises in the conduct of first-in-human studies to Phase IV and extended access programs across a broad range of haematology and oncology indications and has participated in more than 400 studies.

The Basil Hetzel Institute for Translational Health Research

The purpose-built Basil Hetzel Institute for Translational Health Research is the productive research arm of The Queen Elizabeth Hospital. It is located opposite the main campus of The Queen Elizabeth Hospital, just 8 minutes from the Royal Adelaide Hospital. Research themes include cardiovascular disease, cancer, chronic inflammatory disease, population epidemiology, transplantation immunology, vascular surgery, drug response, stroke, as well as surgical technologies and training.

Over 180 researchers in more than 25 research groups have strong links to clinical divisions within The Queen Elizabeth Hospital, underpinning translational health research. The 'bench-to-bedside' approach is at the forefront of an emerging area of medical science that aims to improve public health through collaborative discoveries and innovations in patient care, education and research.

The Basil Hetzel Institute for Translational Health Research has long-standing teaching and research affiliations with Adelaide University and Flinders University, which offer a range of undergraduate and postgraduate research training opportunities.

Supported areas include:

- cardiometabolic
- inflammatory bowel disease
- intensive care
- memory
- oncology
- surgery.

Southern Adelaide Local Health Network (SALHN)

The Southern Adelaide Local Health Network (SALHN) provides care for approximately 350,000 people living in the southern metropolitan area of Adelaide as well as providing a number of statewide and regional services. It has a strong reputation for the quality of its scientific and medical research.

The SALHN Research Hub, a critical mass of research and clinical trial service, provides an environment that promotes collaboration in research and improvement. The Hub aims to work with partners to make SALHN a premier and preferred site to conduct investigator-initiated research and sponsored clinical trials across a broad range of disciplines.

Currently, over 300 clinical trials are being conducted across more than 60 departments, including but not limited to:

- gastroenterology
- haematology
- medical oncology and mental health
- neurology
- respiratory medicine.

Flinders Medical Centre

Part of the Southern Adelaide Local Health Network (SALHN), Flinders Medical Centre (FMC) is the largest hospital in the southern metropolitan area of Adelaide and one of two major trauma centres in the state with around-the-clock emergency retrieval service bringing patients to the hospital by road or helicopter.

FMC counts more than 5,000 skilled staff providing an extensive range of services for patients of all ages.

The hospital is co-located with the Flinders University School of Medicine and Flinders Private Hospital, and is also the base for the South Australian Eye Bank. FMC has earned an international reputation as one of Australia's finest public teaching hospitals and a centre for research excellence.




Image courtesy of Meaghan Coles/SAHMRI

Clinical trials

The Department of Medical Oncology at FMC provides a comprehensive specialist service for patients with cancer. The Oncology Team at FMC treat patients diagnosed with any solid-tumour cancers, using their team of Allied Health professionals to support patients and carers with physical and psychological needs. The Department of Medical Oncology is involved in a number of clinical trials investigating new or potentially improved cancer treatments. Treatment trials for most common cancers including breast, prostate, metastatic melanoma, pancreas, lung, colon and gastricoesophageal cancer are in progress.

Other supported areas of research include:

- audiology
- cardiology
- cardiothoracics
- gastroenterology
- Haematology Clinical Trials Unit (HCTU)
- hepatology
- Intensive Care Unit (ICU) Clinical Trials Unit
- neurology
- ophthalmology
- orthopaedics and trauma
- palliative care research
- renal
- respiratory
- rheumatology
- Southern Adelaide Diabetes and Endocrine Services (SADES) Clinical Research.

Northern Adelaide Local Health Network (NALHN)

The Northern Adelaide Local Health Network (NALHN) delivers services to more than 400,000 people living in the north and north-eastern suburbs and regional areas of Adelaide. These areas of currently have the highest population growth in South Australia, expected to grow to over 456,000 people by 2030, with every age group experiencing an increase.

NALHN's major redevelopments are taking shape, with the $130 million Modbury Hospital upgrade and the $47 million Lyell McEwin Hospital (LMH) expansion well underway, increasing health care capacity in the north and north-east.

NALHN includes the Lyell McEwin Hospital (LMH) and Modbury Hospital, major tertiary hospitals in South Australia, a range of sub-acute and primary health care services and a number of state-wide services.

Clinical trials

NALHN has a broad range of clinical trial facilities, dedicated clinical trial managers for sponsored studies, and specialist research groups for the areas including below:

- Northern Adelaide Neurology Clinical Trial Unit
- Northern Adelaide Cancer Centre Clinical Research Unit
- Lyell McEwin Hospital Intensive Care Research Unit
- Lyell McEwin Hospital Clinical Trials Unit.

Lyell McEwin Hospital

The Lyell McEwin Hospital (LMH) is a major tertiary hospital located north of Adelaide, South Australia that provides medical, surgical, diagnostic, emergency and support services.

The LMH Clinical Trials Unit, is a dedicated, purpose-built area within the hospital that runs Phase II-IV clinical trials for many of the world's leading pharmaceutical and biotechnology companies. The Unit upholds stringent observation of the international regulatory requirements that facilitate the practice of the highest standards in clinical research.

The Clinical Trial Unit conducts trials and has a dedicated research team for the following indications:

- cardiology
- endocrinology
- gastroenterology
- gastroenterology and hepatology
- psychiatry
- renal
- respiratory.

Trial staff are Good Clinical Practice (GCP)-certified and highly experienced in the use of electronic data capture, electronic capture patient reported outcomes (PROs), conducting ECGs, venepuncture, processing and shipping laboratory samples.

Women's and Children's Health Network (WCHN)

The Women's and Children's Health Network (WCHN) is South Australia's leading provider of specialty care and health services for women, babies, children and young people, and their families.

Women's and Children's Hospital

The Women's and Children's Hospital is South Australia's largest specialist facility for women's and children's health. It is South Australia's leading provider of care for children with acute and chronic conditions in South Australia and the state's largest maternity and obstetric service.

Highly regarded as a centre for research, the Women's and Children's Hospital works with all three South Australian universities in the training of hundreds of health professionals each year. The Women's and Children's Hospital aims to be a leader in quality health research, partnering with other agencies, and translating research into innovative and improved services.

WCHN is home to over 200 researchers, currently undertaking more than 400 projects, with over 200 publications every year.

Clinical trials

World-leading clinical trials conducted at the Women's and Children's Hospital in departments and units are including but not limited to:

- Department of Anaesthesia
- Department of Endocrinology
- Department of Gastroenterology
- Department of Neurology and Clinical Neurophysiology
- Department of Respiratory and Sleep Medicine
- Department of Rheumatology
- Michael Rice Centre for Haematology and Clinical Oncology
- Paediatric Emergency Department (PED)
- Robotics Unit
- Women's and Babies' Unit (WABs).

Research organisations

South Australian Health and Medical Research Institute (SAHMRI)

South Australian Health and Medical Research Institute (SAHMRI) is the state's flagship health and medical research institute, focused on delivering better and more equitable healthcare through four major research themes: precision cancer medicine, lifelong health, women and children, and Aboriginal health equity. It is home to over 800 medical researchers, partners, students and support staff.

SAHMRI has extensive expertise in clinical trials and acts as a key resource for conducting and coordinating them. SAHMRI's Clinical Trials Platform, along with the Biostatistics Unit, offers professional services and support to researchers and industry sponsors at all stages of the clinical trial process, including grant development, statistical assistance, and all aspects of trial design and implementation. Their goal is to speed up the translation of research into real-world benefits by delivering exceptional, participant-focused clinical trial services and support.

Registry Centre

The SAHMRI Registry Centre offers a valuable and extensive resource of translational and observational research data. It unites a network of registries, including those within SAHMRI and external member registries, covering patient populations across South Australia, Australia, and New Zealand.

Clinical trials

SAHMRI has a well-established reputation in the conduct and independent oversight of local, national, and international Phase Ib to IV clinical trials across a diverse range of therapeutic areas, including cardiology, oncology, nutrition, metabolic disorders, immunology, paediatrics, pregnancy and medical devices.

The Clinical Trials Platform provides:

- easier, more equitable access to trial involvement for patients and the public
- innovative ways to design and conduct clinical trials that prevent disease or deliver treatments faster by using new and emerging technologies
- support for researchers and industry sponsors who need assistance at any stage of the clinical trial life cycle, which includes grant development, statistical support and all aspects of clinical trial design and conduct
- support for rapid and efficient study startup, including assistance with ethics submissions, contract development and negotiation
- high-quality systems and processes that underpin clinical trial conduct to ensure alignment with best practice examples.

Preclinical and Imaging Research Laboratories

SAHMRI is home to the Preclinical and Imaging Research Laboratories, and Clinical and Research Imaging Centre and can work with universities, institutions, and industry to progress therapies and imaging agents through the translational pipeline, from preclinical studies to the clinic.

Flinders Health and Medical Research Institute (FHMRI)

As a world-class research institute, FHMRI is leading life-changing medical and health research at Flinders University. They focus on addressing some of the most pressing health challenges of our time, driven by the ambition to eliminate disease, combat health inequities and improve outcomes for all.

FHMRI is unique - it has Australia's most extensive network of rural and remote campuses, with deep community partnerships across South Australia and the Northern Territory. In SA they are in close partnership with the clinical services at the Flinders Medical Centre and Flinders Private Hospital. This integration of research, education and healthcare enables strong collaboration between researchers and clinicians, accelerating the translation of discoveries into improved patient care.

The institute's primary hub is in the Health and Medical Research Building (HMRB), which houses cutting-edge laboratory and clinical research facilities, technology platforms (such as the SA Genomics Centre, proteomics, flow cytometry, microscopy), enabling platforms including the Flinders University Clinical Trials Research Unit, the Statistics, Epidemiology and Data Analytics Unit, and pre-clinical facilities for over 400 researchers.

FHMRI's research strengths include:

- Sleep Health Flagship Program – World-leading, transdisciplinary research advancing understanding of sleep, sleep disorders and developing new treatments to improve sleep health.
- Eye and Vision Flagship Program – Research focused on genetic risk prediction and early intervention for conditions such as glaucoma and diabetic retinopathy, alongside work in inflammatory and infectious eye diseases.
- Health Equity Impact Program – Research addressing health inequities with a strong focus on Aboriginal and Torres Strait Islander health and public health.
- Cancer Impact Program – Home to leading oncology clinical trialists, with research spanning population screening, high-risk surveillance, cancer prevention and survivorship.
- Neurosciences – An emerging area of strength focusing on neurodegenerative disease, the gut–brain axis, pain research, and the development of new therapies and diagnostics.

Flinders University Clinical Trials Research Unit

Flinders University Clinical Trials Research Unit provides expert, specialised and patient-centred clinical research services and support. The team offers clinical research and professional expertise to help advance research outcomes. They are multi-disciplinary specialists ready to assist in refining proposals, collaborating, scaling, budgeting, designing and delivering impactful clinical research.


The Unit can harness existing strengths and incorporate modern methodologies to develop and implement clinical research effectively, converting it into evidence that supports the translation of research into improved health services and community outcomes.

The expertise spans all stages of the research timeline, including proposal development, research design, execution, collaboration, and budgeting. The team has decades of combined experience in conducting studies in accordance with protocols, standard operating procedures (SOPs), and good clinical practice (GCP) guidelines.

Flinders University Clinical Trials Research Unit supports clinical research delivery across a wide range of therapeutic areas, whether for industry-funded studies or investigator-driven grant funded research, at local, national or international levels.

The Unit also has expertise in the conduct of community-based pragmatic trials and implementation trials.

Image courtesy of FHMRI



Bragg Centre


Located in the heart of Adelaide, within Adelaide BioMed City, the Australian Bragg Centre provides unmatched accessibility to a world-class, highly connected health and life sciences precinct that links with the most complete clinical trial ecosystem in Australia,
world-leading AI and data analytics capabilities and
a thriving cluster of medtech companies.

PARC Clinical Research (Adelaide University/ CALHN)

PARC Clinical Research, led by Professor Guy Ludbrook, is a high-acuity clinical trials unit within the Royal Adelaide Hospital (CALHN) and is developed in collaboration with Adelaide University. This University-based research group conducts specialised research across multiple disciplines and undertakes contract clinical research for the pharmaceutical and biotech industries. The unit aims to provide a safe and suitable environment for academic clinical studies while meeting the continuing demand for high-quality clinical research infrastructure in the South Australia, building research capacity, and fostering healthcare innovation and collaboration.

PARC has extensive experience in conducting clinical trials across a broad range of therapeutic areas and development stages, from Phase I through to Phase IV. PARC has extensive experience in the management of compounds with narrow therapeutic indices, such as opioids and products in the early phases of development, which often require specialised monitoring and management. In addition, PARC's highly specialised clinical facility is equipped for intensive monitoring of high-risk therapies, with non-hospital allocated beds for overnight and participant studies. The facility's expertise also extends to the dosing and handling of Schedule 8, intravenous, and infusion therapies.

Located within the Royal Adelaide Hospital and complementing other trials units within the Health Precinct, PARC has access to a large number of specialist clinicians, many of whom require a flexible and unique facility such as PARC to conduct their clinical research studies or who can provide patient referrals. PARC provides safe, high-quality facilities with ready-access to clinicians and diagnostic services for the management of a wide range of medical conditions. The experienced nursing staff, combined with the research expertise of the unit, ensures that trials are conducted to the highest standards of care and safety.



Molecular Imaging and Therapy Research Unit (MITRU)

The Molecular Imaging and Therapy Research Unit (MITRU) is dedicated to the research, development and manufacture of radiopharmaceuticals. Part of SA Health, MITRU is home to South Australia's only cyclotron, a particle accelerator that produces radioactive isotopes for medical imaging, treatment and research. MITRU supplies radiopharmaceuticals to hospitals and imaging centres across Australia, supporting patient care, research and clinical trials.

MITRU is GMP-accredited by the Australian Therapeutic Goods Administration (TGA) as a radiopharmaceuticals manufacturer and, in a world-first for cancer imaging, it was the first recipient of a TGA licence to manufacture fluorinated prostate specific membrane antigen for clinical use in 2019.

MITRU specialises in positron emission tomography (PET) imaging tracers. These tracers are bound to an appropriate radionuclide and target specific cells in the body. The patient is then scanned, and the emitted radiation is detected by a PET scanner. The scanner then combines the reading with a CT scan to show where in the body the target cells are located. Tracers used in PET imaging include those used to diagnose cancer as well as Alzheimer's and Parkinson's diseases. The radioactive isotope linked to the tracer is either produced using MITRU's cyclotron (i.e., Fluorine-18, Copper-64, Zirconium-89) or sourced externally (i.e., Lutetium-177, Gallium-68).

Tracers used in PET imaging of cancer can also be bound to radionuclides that can be used to treat cancer. This field of medical research, theragnostics – a combination of therapy and diagnostics – is a strong focus of the MITRU facility and its many partnerships with industry.

South Australian Comprehensive Cancer Network (SACCaN)

The Commission on Excellence and Innovation in Health (CEIH) in South Australia is leading the establishment of the South Australian Comprehensive Cancer Network (SACCaN). The CEIH is a uniquely positioned independent government agency established to lead and foster innovation and improvements in healthcare, by building diverse connections across the broad health ecosystem.

SACCaN drives and connect cancer care across South Australia, from prevention and early detection through to treatment and beyond. The network brings together clinicians, researchers, policy makers, service providers, and community organisations across both public and private sectors to support a more connected and coordinated cancer system. The network is guiding the implementation of the South Australian and Australian Cancer Plans and serving as the peak body to the Australian Comprehensive Cancer Network, to ensure national alignment. SACCaN is strengthening cancer care in South Australian by building a robust and innovative cancer data ecosystem to enable continuous improvement alongside active involvement of people with lived experience of cancer and their families to ensure a patient centered approach.

Clinical trials are a core part of delivering high quality cancer care. SACCaN is leading work to support a more consistent, statewide approach to how cancer clinical trials can be available to all South Australians, by working with clinicians, researchers, Local Health Networks (LHNs), stakeholders and consumers to design a statewide cancer clinical trials hub. Over time, this will help ensure all South Australians have equal access to clinical trials and the opportunity to benefit from the latest cancer research, therapies and treatments.



South Australian immunoGENomics Cancer Institute (SAiGENCI)

The South Australian immunoGENomics Cancer Institute (SAiGENCI) is an independent medical research institute focusing on cancer research and clinical trials, including new cutting-edge technologies in immunotherapies and genomics.

SAiGENCI is jointly resourced by the Australian Department of Health, Central Adelaide Local Health Network and Adelaide University. The Institute collaborates with centres of excellence across the globe, delivering world-class and life-changing treatments and outcomes for cancer patients.

SAiGENCI's objectives include:

- forging strong research collaborations
- developing and testing new technologies and discoveries
- improving treatment and care options for people living with cancer
- training South Australian clinicians
- commercialising new discoveries.

Principal research areas include:

- drug discovery and development
- tumour inflammation and immunotherapy
- computational systems oncology
- epigenetics
- single cell and spatial technologies.

Case study: The Daisy Project - Advancing radiation protection and cancer treatment

In a recent major outcome from SAiGENCI and the Adelaide University, researchers of these institutions developed SAi001, which offers critical protection from the immediate and lasting impacts of radiation with potential uses for the space, defence and mining industries and for cancer treatment. Under The Daisy Project, the plant-derived active pharmaceutical ingredient of SAi001 exhibits radiation protection effects while also having anti-tumour and anti-inflammatory activities.

The project team is currently working with industry partners in Australia and the United States to progress the product to human clinical trials, regulatory approvals and commercial production after extensive pre-clinical pharmaceutical studies' promising results.

Another focus for the team is a second drug called SAi002, which is predicted to be a ground-breaking cancer treatment that could help patients with metastatic cancers, including breast, prostate, and lung cancer as well as haematological cancers-like lymphomas and leukemias.

Case study: The IMAGENDO® study: revolutionising endometriosis diagnosis through AI

Two Adelaide University research institutes – the Robinson Research Institute and the Australian Institute for Machine Learning (AIML) – are harnessing the power of artificial intelligence (AI) to revolutionise the diagnosis of endometriosis. By combining ultrasound, magnetic resonance imaging (MRI), and AI, the researchers aim to make IMAGENDO® a cost-effective, accessible, and accurate new way to reduce the need for surgery and the time it takes to receive a diagnose.

The AI algorithm is trained using a large dataset of ultrasounds and MRIs, enabling it to recognise endometriosis markers with accuracy comparable to that of a specialist endometriosis doctor. This will enable other sonographers and doctors to achieve similar diagnosis rates.

With earlier diagnosis, IMAGENDO® technology will lead to prompt treatment and better quality of life by avoiding unnecessary hospitalisations and repetitive surgery. IMAGENDO® could also help preserve fertility by enabling early interventions such as egg freezing.

IMAGENDO® is increasingly recognised globally and is expanding across Australia and internationally with collaborations in North America, South America, Southeast Asia, the United Kingdom, and Europe.

Source: timeshighereducation.com, Harnessing AI to revolutionise endometriosis diagnosis, 2026

Robinson Research Institute


The Robinson Research Institute at Adelaide University is a collective of internationally leading researchers addressing reproductive and early life origins of health and disease with world-leading research in:

- child and adolescent health.
- early origins of health
- fertility and conception
- pregnancy and birth.

Their 45+ research teams are uncovering how events and circumstances before birth and during early life impact an individual's healthy development, their susceptibility to disease and their resistance to adversity. These discoveries are being used to develop effective interventions to protect children and improve their health prospects throughout life.

Their research is novel as it includes the critical period prior to conception. As the preconception period is critical for a healthy pregnancy and establishing the health trajectory of the developing fetus, they also consider the health, environment and social circumstances of prospective parents.

Robinson Research Institute's 400+ members manage research projects, clinical trials and cohort studies, and collaborate across many disciplines including biomedical, clinical, social, and epidemiological science to generate new discoveries that will improve reproductive health in parents and tackle life-long health in children.



Bradley Building, Adelaide University

Leading the nation in AI for healthcare

South Australia is well-positioned to become a global leader in medical artificial intelligence (AI) due to its wealth of digital health assets and research capability. Adelaide serves as Australia's hub for AI and data analytics innovation and is leading the country in AI for healthcare.

With a robust healthcare system and advanced data management capabilities, the state is uniquely positioned to develop, apply, and commercialise AI solutions for global health problems. South Australia is embracing AI's potential to deliver a major transformative impact to healthcare.

South Australia has a proven track record of effective collaboration among government, industry, and academia, resulting in greater efficiency in the health system, optimising operational and clinical decision-making, and improving patient outcomes.

Its integrated health ecosystem, combined with its globally unique datasets, gives the state a clear advantage in AI-driven personalised healthcare innovation. Key assets supporting this industry shift include world-leading hi-tech capabilities, SA Pathology's biospecimen assets, and a database of 32.5 million unique patient records, containing over 21 billion data points and more than 80 years of historical pathology data.

Major AI research capabilities in South Australia include:

- The Australian Institute for Machine Learning (AIML)
- Australian Research Centre for Virtual and Interactive Environment (IVE)
- Amazon Web Services
- Adelaide University's Centre for Augmented Reasoning and Industrial AI Research Centre.

Australian Institute for Machine Learning

Australia's first facility solely dedicated to artificial intelligence research. The Australian Institute for Machine Learning (AIML), one of Australia's largest AI capabilities, conducts globally competitive research and development in machine learning, artificial intelligence, computer vision and deep learning.

AIML is recognised for its world-leading research in AI ethics and safety in health capability, particularly in clinical imaging. It is partnering with the world's leading healthcare companies to ensure that patient safety is at the centre of the digital health innovation that will transform health outcomes for the global community. Together with leading global companies including Roche, GSK,Sanofi, and Medtronic, AIML is pushing the frontier of precision health.



Australian Institute for Machine Learning



QuantX Labs


Industrial AI Research Centre

Adelaide University's Industrial AI Research Centre is at the forefront of transforming healthcare with innovative AI and data-driven solutions. Their multi-disciplinary team of experts collaborates with healthcare professionals and organisations to revolutionise patient care, diagnostics and medical research.

Key focus areas include health data analytics and informatics, digital health and the development of AI-driven algorithms, with applications in healthcare decision-making and patient centric approaches.

Australian Research Centre for Interactive and Virtual Environments

The Australian Research Centre for Interactive and Virtual Environments (IVE) is a unique alignment of computer science, engineering, art, architecture and design. IVE is responding to the challenge of increased global demand for augmented reality (AR) and virtual reality (VR) technologies, with leading research including wearable computing, interface design, empathic computing, 3D visualisation, perception and telepresence. Their Design Research for Health and Wellbeing (DRHW) group is home to a cross-disciplinary network of professionals, including researchers, computer scientists and healthcare workers, merging design, healthcare, and immersive digital experiences to help tackle major health and wellbeing issues



SAHMRI | Image courtesy of Henry Trumble

Case studies: AI is changing the way we think health

Harnessing AI for preventative healthcare

Leveraging SA Pathology's 80-year long continuous pathology data and South Australia's advanced capabilities in emerging technologies, research labs in Adelaide have developed AI systems capable of identifying health risks in high-risk patients before they occur.

Based at the Royal Adelaide Hospital, researchers from AIML, SA Pathology and IVE built a software system that alerts doctors if a patient is at higher risk of requiring hospitalisation.

By looking at the blood tests showing early signs of prediabetes and, if there are patterns and trends in certain geographic hotspots, doctors in those areas can get an early warning about what to focus on.

SA Pathology aims to further increase the use of AI to improve preventative health care, speed up manual time-consuming tasks and lower costs to deliver better public health outcomes, focusing on three key areas: clinical decision making, disease surveillance and population health management.

In addition to those three key areas, AIML's engineers are working towards ways of improving digital pathology services. Areas of interest include cell counting through a deep learning network to capture pathologists' annotations to learn how to trace each cell in an image, reducing the time pathologists need to work on pathology images.

SMART-PH – Digitising information for practice in public health

In a milestone demonstration of South Australia's AI expertise and capabilities, Flinders University is leading the development of Australia's first AI-driven integrated public health and clinical data platform, SMART-PH (DigitiSing InforMAtion for PRacTice in Public Health).

Designed to tackle the lack of real-time, high-quality public health data and pressing healthcare challenges, including pandemics and natural disasters, the SMART-PH project will create a common digital infrastructure capable of eliminating data silos and enabling real-time collaboration in healthcare decision-making. This is also particularly beneficial for improving healthcare in remote and rural regions.

Launched in 2024, the project was awarded nearly A$3 million from the Medical Research Future Fund 2023 National Critical Research Infrastructure initiative. Implementation and evaluation with key South Australian partners is scheduled from 2027 to 2029.

Source: news.flinders.edu.au, AI driving a SMART future for public health, 2024

Global technology leaders choose South Australia

These global companies have established a presence in South Australia to leverage our unique talent and ecosystem, driving their operations well into the future.

Qantas

Qantas is establishing a new Product Innovation Centre in Adelaide, supported by the South Australian Government. The purpose-built centre will host more than 420 high-value technology roles spanning product management, digital experience design, software engineering, data and AI, and related technology functions within three years. Qantas has partnered with Adelaide University to establish graduate recruitment pathways into the centre.

"Technology and AI is critical to lifting the customer experience at every part of the journey, from booking to inflight and baggage collection. This new hub will bring the best Australian skilled talent together to build digital products and experiences that make travel easier and more personalised. Adelaide gives us access to world-class universities, a thriving tech community, and the ability to scale our in-house capability. It's an investment in Australian innovation that will deliver real benefits for our customers."

Vanessa Hudson, CEO,
Qantas Group

Deloitte

Deloitte pioneered Australia's first Centre for Innovation and Technology in Adelaide, which has grown to a workforce of 800 people. Deloitte also partnered with Adelaide University to establish The Academy by Deloitte, offering internship experiences and specialised undergraduate courses.

"We have chosen Adelaide as the home of our first Australian Centre for Innovation and Technology because we have enormous confidence in the South Australian economy and the exceptional talent market that exists in the region."

Hendri Mentz, Managing Partner,
Adelaide Office, Deloitte



Qantas flight over Adelaide oval

NextDC

NextDC unveiled its first Tier IV Data Centre in Adelaide in September 2024 to position for data's critical role in advancing South Australia's progress in advanced industries including aerospace, defence, health, and mining and resources.

"We're excited to invest in South Australia's future as a digital hub for innovation and sustainability. The State Government's commitment to a digital-driven, green economy supporting cutting-edge technology aligns with our vision to build Australia's leading digital infrastructure platform here in Adelaide."

David Dzienciol, Chief Customer and Commercial Officer, NEXTDC

Amazon Web Services

Amazon Web Services established its Australian Applied Sciences team in Adelaide explicitly to work with AIML on developing new AI applications, co-locating at Lot Fourteen alongside a growing ecosystem of AI and space companies.

"Amazon Web Services recognise that South Australia has a rich community of both innovation and entrepreneurship, and we're excited to continue to support our customers and partners in South Australia out of our office in the innovation district of Lot Fourteen in Adelaide."

Rianne van Veldhuizen,
Vice President & Managing Director,
AWS Australia-New Zealand,
Amazon Web Services ANZ

CommBank

CommBank established the CommBank Centre for Foundational AI Research at Lot Fourteen (Australia's largest private-sector commitment to foundational AI) in partnership with AIML. Leading AI researchers will be recruited to the centre and CBA through hybrid appointments, which will combine academic rigor with industry relevance. CBA's CIO for Technology noted the AI investment paid for itself in just three weeks by applying new techniques to transaction embeddings.

"The focus on cyber security and AI within Adelaide and Lot Fourteen, and the depth of the local talent pool in these topics are big attractors for us. AI and data are key to the next generation of digital personalisation, and the local focus on Augmented Reasoning, in particular, is very exciting when we think about how we can use AI technology to better empower our staff to serve our customers."

Brendan Hopper, CIO for Technology,
Commonwealth Bank of Australia

World-class innovation places

Our sectors co-exist in hi-tech hubs and research centres, forging collaborative ecosystems that open doors and inspire new ways of thinking.

Roseworthy Campus 61km from central business district

Part of the Adelaide University, a hub of undergraduate teaching, postgraduate training, research and clinical services with an international reputation for excellence in dryland agriculture, natural resource management and animal production.

Technology Park 17km from central business district

Hub for systems development and integration, information communications technology, advanced manufacturing and electronics, and home to over 100 small to medium enterprises, multinationals and start-ups.

Adelaide BioMed City Adelaide central business district

With more than 2,000 researchers and 10,000 staff, Adelaide BioMed City brings together institutes and centres for health and life sciences, clinical care, research, education and industry. This A$3.8 billion medical innovation district includes the Royal Adelaide Hospital, the Women's and Children's Hospital, the South Australian ImmunoGenomics Cancer Institute (SAiGENCI), the South Australian Genomics Centre (SAGC), and Flinders University's city campus. The district also includes Adelaide University's institutions: SAHMRI, the College of Health and the Centre for Cancer Biology.

Adelaide University Adelaide central business district

Adelaide University is Australia's second largest university and ranked in the top 100 globally. With more than 180 years of collective experience and achievement. Adelaide University is leveraging the capabilities and resources of its foundation institutions to launch bright futures and breakthroughs. Distinguished alumni of five Nobel Laureates, over 100 Rhodes Scholars, including Australia's first Indigenous recipient, and Australia's first female prime minister and Supreme Court judge.

Lot Fourteen Adelaide central business district

Based in Adelaide's central business district, Lot Fourteen is a A$790 million flagship innovation district and home to 160+ organisations across defence, space, cyber and critical technologies including the Australian Space Agency, Australasian Space Innovation Institute, Defence and Space Landing Pad, Stone & Chalk, Australian Institute for Machine Learning and the Australian Cyber Collaboration Centre.

Tonsley Innovation District 12km from the central business district

Home to high-value manufacturing industries including defence, health, medical devices and assistive technologies, clean tech and renewable energy, software and simulation, minerals and energy services. Home to Flinders Factory of the Future advanced manufacturing test bed, South Australia Drill Core Reference Library, SA-H2H Hydrogen Technology Cluster, Hydrogen Park SA, BAE Systems Maritime Australia, Micro-X and the Medical Device Research Institute.

Flinders University 13km from central business district

For over 50 years, Flinders has been a centre of inspiring achievement, from pioneering research and excellence in teaching to the positive impact the university has on the communities it serves. Three main campuses provide future-focused, internationally recognised degrees with flexible study options. Established in 2019, Flinders Health and Medical Research Institute (FHMRI) assembles top Australian research experts, working on some of medicine's biggest mysteries, driving new discoveries to eliminate disease and improve health.

Invest SA



SAHMRI | Image courtesy of Meaghan Coles

Let's talk

Please contact Invest SA

Sandra Hack, PhD

Business Development Manager
Health and Medical Industries

M: +61 435 100 052
E: sandra.hack@sa.gov.au

Muhammad Tani Tabiin, PhD

Business Development Manager
Health and Medical Industries

M: +61 470 490 315
E: muhammad.tabiin@sa.gov.au

Iolanda Principe, PhD

Business Development Manager
Health and Medical Industries

M: +61 435 961 933
E: iolanda.principe@sa.gov.au

Published August 2026 | Revised October 2026

No responsibility for any loss or damage caused by reliance on any of the information or advice provided by or on behalf of the state of South Australia, or for any loss or damage arising from acts or omissions made, is accepted by the state of South Australia, their officers, servants or agents. Produced by the Government of South Australia
© August 2026. Content correct at time of printing.

invest.sa.gov.au